G1 Therapeutics.

Shares of G1 Therapeutics dropped sharply after it reported disappointing clinical trial results for its lead cancer drug. The company ended a phase 3 trial because the drug failed to...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT